MAZE (Maze Therapeutics) ROC (Joel Greenblatt) %: -310.57% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $29.33
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics ROC (Joel Greenblatt) %?

Maze Therapeutics MAZE -1.67% 14 ROC (Joel Greenblatt) % is -310.57% as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,323 Biotechnology companies, Maze Therapeutics ranks worse than 55.93% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Maze Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -310.57%.

The historical rank and industry rank for Maze Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

MAZE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -518.9   Med: -263.96   Max: 177.46
Current: -457.18

During the past 4 years, Maze Therapeutics's highest ROC (Joel Greenblatt) % was 177.46%. The lowest was -518.90%. And the median was -263.96%.

MAZE's ROC (Joel Greenblatt) % is ranked worse than
55.93% of 1323 companies
in the Biotechnology industry
Industry Median: -296.6 vs MAZE: -457.18

Maze Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Maze Therapeutics  (NAS:MAZE) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Maze Therapeutics ROC (Joel Greenblatt) % Related Terms


Maze Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics ROC (Joel Greenblatt) % Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-269.30 -258.62 177.46 -518.90

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.71 -516.35 -486.83 -589.86 -310.57

MAZE vs AVBP, DMRA, CAPR: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Maze Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maze Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's ROC (Joel Greenblatt) % falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.8) - (6.908 + 0 + 10.853)
=-9.961

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20 + 0 + 7.397) - (10.983 + 0 + 5.415)
=10.999

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Maze Therapeutics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-93.368/( ( (25.16 + max(-9.961, 0)) + (23.967 + max(10.999, 0)) )/ 2 )
=-93.368/( ( 25.16 + 34.966 )/ 2 )
=-93.368/30.063
=-310.57 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -310.57% mean?
Maze Therapeutics (MAZE) has a ROC (Joel Greenblatt) % of -310.57% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Maze Therapeutics and its competitors. According to the industry distribution chart, Maze Therapeutics ranks #740 out of 1323 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Maze Therapeutics' ROC (Joel Greenblatt) % too high?
Maze Therapeutics' current ROC (Joel Greenblatt) % is -310.57%. Based on the distribution chart, Maze Therapeutics ranks #740 out of 1323 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' ROC (Joel Greenblatt) % compare to AVBP and DMRA?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #740 out of 1323 companies for ROC (Joel Greenblatt) %. This places Maze Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current ROC (Joel Greenblatt) % is -310.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current ROC (Joel Greenblatt) % of -310.57%. The current ROC (Joel Greenblatt) % is -310.57%. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current ROC (Joel Greenblatt) % is -310.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.33
Price